Dr Martijn Lolkema talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the selective inhibitor OMO-1 and its effect in patients with c-MET aberrations which are found in lung cancer.
He describes the mechanism, tolerability and safety of this drug in c-Met driven cancers, which was found to target these mutations effectively.
Dr Lolkema discusses the next steps for this study, which include expanding the patient cohort and combining this drug with other types of therapies.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.